Compare KFRC & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KFRC | BWAY |
|---|---|---|
| Founded | 1962 | 2003 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Professional Services | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 499.7M | 450.8M |
| IPO Year | 1996 | N/A |
| Metric | KFRC | BWAY |
|---|---|---|
| Price | $26.15 | $13.50 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $38.50 | $13.25 |
| AVG Volume (30 Days) | ★ 271.6K | 133.2K |
| Earning Date | 04-27-2026 | 03-11-2026 |
| Dividend Yield | ★ 6.19% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.96 | N/A |
| Revenue | ★ $1,329,007,000.00 | N/A |
| Revenue This Year | $2.78 | $301.23 |
| Revenue Next Year | $4.32 | $24.33 |
| P/E Ratio | ★ $13.21 | $81.98 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $24.49 | $7.84 |
| 52 Week High | $50.14 | $26.63 |
| Indicator | KFRC | BWAY |
|---|---|---|
| Relative Strength Index (RSI) | 37.98 | 30.06 |
| Support Level | $25.01 | $11.55 |
| Resistance Level | $28.41 | $16.14 |
| Average True Range (ATR) | 1.13 | 0.90 |
| MACD | 0.16 | -0.21 |
| Stochastic Oscillator | 30.15 | 13.99 |
Kforce Inc is a solutions firm specializing in technology, finance, accounting, and other professional staffing services. The company operates two business segments: the Technology segment, which provides talent solutions with candidates skilled in areas including systems/applications architecture and development, data management and analytics, business and artificial intelligence, machine learning, project and program management, and network architecture and security. The FA segment offers consultants in traditional finance and accounting roles such as finance, planning and analysis; business intelligence analysis; general accounting; transactional accounting, business and cost analysis; and taxation and treasury. The majority of revenue is earned through the Technology segment.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.